Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: A strong positive correlation between plasma apolipoprotein (apo) C-III and triglyceride concentrations has been invariably observed in human and animal studies. The hypertriglyceridemic effect of apo C-III has been conventionally explained by its extracellular roles in inhibiting lipolysis catalysed by lipoprotein lipase and attenuating triglyceride-rich lipoprotein clearance through receptor-dependent and/or independent mechanisms. However, recent experimental evidence suggests that apo C-III may also play an intracellular role in promoting hepatic triglyceride-rich lipoprotein production. RECENT FINDINGS: Kinetic studies with humans and genetically modified mice have shown that apo C-III is linked with increased production of triglyceride-rich lipoproteins, such as very-low-density lipoprotein 1 (VLDL1). Mutational studies on human apo C-III variants (originally identified in humans with hypotriglyceridemia or hyperalphalipoproteinemia) provide the structure-function analysis of human apo C-III, demonstrating that loss-of-function mutations within human apo C-III impair the assembly and secretion of triglyceride-rich VLDL1 under lipid-rich conditions. SUMMARY: The current review summarizes recent experimental evidence for an intrahepatic role of human apo C-III in promoting mobilization and utilization of triglyceride during VLDL1 assembly/secretion. Understanding mechanisms by which hepatic apo C-III expression is regulated under insulin resistance and diabetic conditions will lead to better and more rational strategies for the prevention and treatment of diabetic hypertriglyceridemia that is closely related to premature atherosclerosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental studies show that apoCIII enhances hepatic assembly and secretion of VLDL, and human kinetic studies have shown an association between apoCIII and VLDL production [47].”
In the citing paper
“Apo C-III is expressed both intestinally and hepatically, circulates with TG-rich lipoproteins, has net deleterious effects on lipoprotein metabolism58–63”
From Clinical review on triglycerides (2020) · cites this paper as [60]
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“fatty acids of adipocyte origin or released from hydrolysis of remnant lipoproteins), as well as endogenous de-novo lipogenesis (DNL), are the major substrate for hepatic triglyceride synthesis [13].”
BackgroundSelective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965 · cited 1×
“Second, the FoxO1 branch of the insulin signalling becomes insensitive to insulin, whereas the DNL (controlled by the SREBP-1c pathway) remains responsive [13,52].”
BackgroundAdiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820 · cited 1×
“2b), a hallmark for diabetic hypertriglyceridemia [54] that often occurs at the initial stage of insulin resistance [55].”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“On the contrary, loss-of-function mutations within the human APOC3 gene have been associated with hypotriglyceridemia [5], hyperalphalipoproteinemia [6], and cardioprotective lipid/lipoprotein profiles in the Old Order Amish population [7].”
BackgroundSacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · cited 1×
“VLDL or LDL containing apo C-III imposes a greater risk to cardiovascular complications [21].”
BackgroundApolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339 · cited 1×
“Unau 0957-9672 2012 Wolters Kluwer Health | Lippincott Williams & Wilk Negative regulators include peroxisome proliferator-activated receptor-a [35], peroxisome proliferator-activated receptor-g [36], farnesoid X receptor [37] and Rev-erba [38].”
BackgroundMaeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313 · cited 1×
“Unautho been observed in Apoc3-null mice [8].”
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309 · cited 3×
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
BackgroundFoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D. H., Slusher, S., Meseck, M., & Dong, H. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32914 · Cited by 282 · cited 2×
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
Background
Cited by
Items 101–102 of 102
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Borutzki, Y., Hagn, G., Bileck, A., Mohr, T. T., Bazett, M., Snow, M., Jones, M., Pankovich, J., Gerner, C., Keppler, B. K., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117238
“40 Both APOC2 and APOC3 are associated with triglyceride-rich lipoproteins, such as VLDLs. 41 Interest-ingly, LGALS3BP (formerly known as Mac-2-BP) was previously identified to bind to tumor-secreted antigens and has immunostimulatory activity, 42 especially via pattern-recognition…”
Metadata
- Authors
- Yao, Z., & Wang, Y.
- Affiliations
- University of Ottawa (CA)
- Corresponding author
- Yao, Zemin
- Venue
- Current Opinion in Lipidology
- Published
- 2012-06
- Volume
- 23
- Issue
- 3
- Pages
- 206-212
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2041953515
- Cited by
- 100
- References
- 60
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 12 · 2014: 10 · 2013: 7 · 2012: 2
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein C-III, hypertriglyceridemia, hypotriglyceridemia, hyperalphalipoproteinemia, insulin resistance, diabetes mellitus, triglyceride mobilization, lipoprotein lipase
- MeSH terms
- Animals, Gene Expression Regulation, Homeostasis, Humans, Liver, Triglycerides, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.